The best of R&I and around the web, handpicked by our editors.
White papers, service directory and conferences for the R&I community.
Web replica of the print magazine.
Medium-Sized Accounts Experience Largest Decrease While Third-Party Litigation Funding Impacts Casualty Lines, CIAB research finds.
Films require a range of insurance policies, depending on unusual hazards, stunts or overseas locations.
Tennis star Maria Sharapova’s admission to a failed drug test resulted in immediate financial repercussions.
Health care facilities must balance safety and security concerns when considering protection methods.
Risk managers struggle and succeed in placing cyber coverage.
Higher education faculty and risk managers must protect students and property without violating freedom of expression.
Risk managers should look at more than price when buying E&S coverage.
Specialty Insurers and their risk management partners find a way to keep historic vessels in use.
Insurance carriers can be doing more to address the risks for student athletes.
Patient communications are necessary to prevent hospital readmissions.
Modeling cyber risk accurately is key to avoiding a subset of D&O claims.
While insureds with losses can expect an increase, others can look forward to level pricing or even modest discounts.
Fitch Ratings expects deteriorating earnings for insurers and only modest improvements for brokers.
Insurance business leaders in 2016 will be expected to both manage change and drive it.
Middle-market companies are being targeted by insurers, but some industry sectors are finding it increasingly difficult to get coverage.
The private insurance market needs to better understand exposure to flooding.
An analysis of EEOC data pinpoints states with risks of employee lawsuits higher than the national average.
Except for cyber, risk managers can expect declining insurance premiums.
Insurance underwriters are an endangered species, according to some projections.
Coral reefs protect against flooding, and coral is used in the creation of heart disease and cancer drugs.